1-(3-chlorophenyl)sulfonylpyrrolidine is a chemical compound with the molecular formula C₁₀H₁₂ClNO₂S.
It is a **sulfonamide derivative**, specifically a **pyrrolidine sulfonamide**, with a 3-chlorophenyl substituent attached to the sulfonyl group.
**Importance in Research:**
While I couldn't find specific research on 1-(3-chlorophenyl)sulfonylpyrrolidine itself, **sulfonamides** in general are important in research due to their diverse applications:
* **Pharmaceutical Chemistry:** Sulfonamides are widely used as **antibacterial agents** (e.g., sulfa drugs). They inhibit the synthesis of folic acid, an essential nutrient for bacterial growth.
* **Organic Synthesis:** Sulfonamides are versatile intermediates in organic synthesis. They can be used to prepare various other compounds through reactions like **sulfonylation**, **amidation**, and **cyclization**.
* **Materials Science:** Sulfonamides are also used in the development of **polymers**, **surfactants**, and **dyes**.
**Potential Applications of 1-(3-chlorophenyl)sulfonylpyrrolidine:**
Considering the compound's structure, it could potentially be investigated for:
* **Pharmacological activity:** The pyrrolidine ring is often found in **medicinal compounds**, and the sulfonamide group could contribute to potential **biological activity**.
* **Synthetic chemistry:** As a sulfonamide, it could serve as a building block for preparing novel compounds with diverse functionalities.
* **Material science:** The presence of the sulfonyl group and the aromatic ring could make it useful in the synthesis of polymers or other materials.
**It's important to note:**
* Without specific research on 1-(3-chlorophenyl)sulfonylpyrrolidine, its actual properties and applications remain unknown.
* Research on this specific compound would need to be conducted to determine its potential uses.
I hope this explanation is helpful!
ID Source | ID |
---|---|
PubMed CID | 890981 |
CHEMBL ID | 1334769 |
CHEBI ID | 109831 |
SCHEMBL ID | 15010078 |
Synonym |
---|
SDCCGMLS-0046385.P002 |
MLS000063405 , |
smr000072725 |
1-[(3-chlorophenyl)sulfonyl]pyrrolidine |
CHEBI:109831 |
AKOS000812279 |
1-(3-chlorophenyl)sulfonylpyrrolidine |
HMS2457E03 |
CHEMBL1334769 |
SCHEMBL15010078 |
bdbm31033 |
cid_890981 |
Q27189133 |
SR-01000262918-1 |
sr-01000262918 |
670271-99-5 |
1-(3-chlorobenzenesulfonyl)pyrrolidine |
CS-0352025 |
1-((3-chlorophenyl)sulfonyl)pyrrolidine |
Z45509034 |
Class | Description |
---|---|
sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 0.0562 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | EC50 (µMol) | 50.0000 | 0.0700 | 1.4650 | 5.1000 | AID718 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7367 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0001 | 1.4693 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 2.1499 | 10.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7367 | 7.0000 | AID718 |
GABA theta subunit | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.0190 | 1.7054 | 7.0000 | AID718 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) |
plasma membrane | Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) |
plasma membrane | Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1333780 | Anticonvulsant activity in Carworth Farm1 mouse assessed as protection against maximal electroshock-induced seizures at 100 mg/kg, ip administered 30 mins prior to 60-Hz current induction | 2017 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1 | Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models. |
AID1333778 | Neurotoxicity in Carworth Farm1 mouse assessed as muscle relaxation up to 100 mg/kg, ip | 2017 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1 | Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models. |
AID1333776 | Neurotoxicity in Carworth Farm1 mouse assessed as somnolence up to 100 mg/kg, ip | 2017 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1 | Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models. |
AID1333777 | Neurotoxicity in Carworth Farm1 mouse assessed as sedation up to 100 mg/kg, ip | 2017 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1 | Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |